We are a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
We utilize a cell-free protein synthesis platform to enable us to uniquely design and produce protein carriers and antigens, the critical building blocks of vaccines, in ways that we believe conventional vaccine technologies currently cannot.
Our pipeline includes pneumococcal conjugate vaccine (PCV) candidates that we believe are the most broad-spectrum PCV candidates currently in development, targeting the $7 billion global pneumococcal vaccine market. Our lead vaccine candidate, VAX-24, is a preclinical, 24-valent PCV that we are evaluating for the prevention of invasive pneumococcal disease, or IPD. VAX-24 includes 11 incremental strains over and above the 13 strains in Prevnar 13®, covering all 24 strains contained in today’s standard of care vaccination regimen for adults, which includes use of both Prevnar 13, a bestin-class PCV, and Pneumovax 23®, a non-conjugated polysaccharide-only vaccine. These 11 incremental strains are responsible for high case-fatality rates, antibiotic resistance and/or meningitis and vaccination with a single broad-spectrum PCV to address all strains could help address this current unmet need.
Our pipeline also includes:
- VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains, including newly emerging strains responsible for IPD and antibiotic resistance;
- VAX-A1, a prophylactic vaccine designed to prevent Group A Strep infections; and
- VAX-PG, a therapeutic vaccine designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease.